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Abstract
Background: The Asthma Symptom Utility Index (ASUI) is a preference-based outcome measure
used in US clinical trials and cost-effectiveness studies for asthma. This study evaluated ASUI
preference weights in Europe to determine whether the multi-attribute utility function, based on
preferences from a US population, is generalizable across countries.
Methods: Data were collected from ninety asthma patients from Italy, France, and the United
Kingdom using the Asthma Control Questionnaire, the Asthma Quality of Life Questionnaire, and
the ASUI. Subjects rated their preferences for 10 asthma health states using a visual analogue scale
(VAS) and a standard gamble (SG) interview.
Results: All multi-symptom states showed statistically significant differences (p < 0.001) between
countries in mean VAS scores. Mean SG utility scores between the US and France and the US and
Italy demonstrated statistically significant differences (p < 0.001) for three states: severe wheeze;
moderate cough and wheeze; and moderate cough and dyspnea. Because of these differences, the
multi-attribute utility functions derived within countries were somewhat different. Despite these
differences, country-specific algorithms captured a similar rank ordering of patients by disease
severity, were strongly correlated (r = 0.971 to 0.995), and demonstrated similar relationships with
symptom and AQLQ scores.
Conclusion: Results of this study suggest that the ASUI may be a complementary patient-reported
outcome for clinical studies and may be useful for applications in cost-effectiveness studies
comparing different asthma treatments.
Background
Patient-reported outcomes, such as patient perceptions of
symptom frequency and severity and their health-related
quality of life (HRQL) are important for clinical manage-
ment and for evaluating new treatments for asthma [1].
These patient based outcomes have been used to evaluate
pharmacologic and behavioral interventions in asthma
[2-5]. Evaluation of the cost-effectiveness of new treat-
ments requires careful collection of medical costs and
assessment of relevant and clinically meaningful out-
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comes from the patient's perspective. While symptom-free
days [6] and quality-adjusted life years can capture overall
effectiveness, these measures may not be sensitive enough
to differentiate among different active treatments for
asthma [7].
The Asthma Symptom Utility Index (ASUI) is a prefer-
ence-based outcome measure that can be used in clinical
trials and cost-effectiveness studies for asthma [7]. It is an
11-item instrument designed to assess the frequency and
severity of four asthma symptoms (cough, wheeze, dysp-
nea, and awaken at night) and side effects, weighted
according to patient preferences. Scoring of the ASUI is
based on a multi-attribute utility function, which uses
utilities as the underlying weighting metric. Utilities rep-
resent patients' preferences for different health outcomes
under conditions of uncertainty [8,9]. For the ASUI, utili-
ties for different asthma health states were assessed using
visual analogue scale (VAS) preference and standard gam-
ble (SG) utility data from patients in the US. The ASUI has
been included in the Improving Asthma Control Trial
(IMPACT), an ongoing, long-term, double-blind parallel
group study conducted in the United States (US) and
sponsored by the National Institutes of Health (NIH) (S.
Sullivan, personal communication).
The objective of the present study was to evaluate ASUI
preference weights in Europe to determine whether the
multi-attribute utility function, based on preferences
derived from a US population, is generalizable across
countries. Comparable preferences and derived ASUI
algorithms would support the use and validity of the ASUI
in multinational clinical trials. As a secondary objective,
we derived and evaluated a multi-attribute utility function
based on the combined data from the US and Europe.
Methods
This study was a cross-sectional survey of a sample of
patients with asthma. All data were collected by trained
interviewers during face-to-face interviews. A total of
ninety patients with asthma were recruited from three
sites, one in the UK, one in France, and one in Italy. All
subjects had to be at least 18 years of age with a diagnosis
of asthma. Each site was asked to recruit 10 mild, 10 mod-
erate, and 10 severe patients, as judged by the clinician
based on Global Initiative for Asthma (GINA) guidelines
for classifying disease severity [10]. In addition, for com-
parative purposes we included clinical and ASUI data
from the original US development study [7].
Measures
The study subjects completed the Asthma Control Ques-
tionnaire (ACQ), the Asthma Quality of Life Question-
naire standardized version (AQLQ-S), and the ASUI.
Culturally and linguistically validated [11] UK English,
Italian and French translations were available for all the
patient reported measures. Subjects also completed a soci-
odemographic questionnaire with questions on gender,
age, education, marital status, comorbidity, and occupa-
tional status. The patients' physicians completed a severity
of asthma rating, based on the GINA guidelines.
Asthma Control Questionnaire (ACQ)
The ACQ [12] was used to evaluate control of asthma
symptoms. This clinical status scale consists of a compos-
ite of asthma symptoms, including awaken at night, wak-
ing with symptoms in the morning, shortness of breath,
wheeze, limitation in activities, spirometry (completed by
clinician), and bronchodilator use. Scores range from 0 to
6, with higher scores indicating more asthma symptoms
and related problems.
Asthma-Symptom Utility Index (ASUI)
The ASUI is an 11-item, preference weighted question-
naire for collecting data on the frequency and severity of
four asthma-related symptoms and any side effects of
medication therapy [7]. The ASUI measures frequency and
severity of cough, wheezing, shortness of breath and sleep
disturbance related to asthma. In the ASUI questionnaire,
subjects are asked about side effects of asthma medication
and the frequency and severity of those they have experi-
enced. The time frame for responses is the past two weeks.
Frequency is measured on a four-point scale (i.e., not at
all, 1–3 days, 4–7 days and 8–14 days) and severity is
measured on a four-point scale (i.e., not applicable, mild,
moderate and severe). A single index score is calculated
which consists of the preference-weighted individual
attribute scores based on a multiplicative multi-attribute
utility function derived from a sample of 161 US asthma
patients (see Revicki et al. [7] for details). ASUI scores
range from 0 to 1.0 with lower scores reflecting greater
symptom problems. ASUI scores vary by disease severity
and are correlated with Asthma Quality of Life Question-
naire scores [7]. The ASUI was translated and culturally
adapted [13] into UK English, Italian and French using an
established methodology [13], including 2 forward and 1
backward translations, 3 independent reviews to resolve
observed differences in translations, and cognitive inter-
viewing with small samples of asthma patients in each
country.
Asthma Quality of Life Questionnaire (Standardized 
version)
The Asthma Quality of Life Questionnaire (AQLQ-S) [14-
16] was designed as a disease specific measure of HRQL in
persons with asthma. It is a self-administered question-
naire that measures symptoms, emotions, environmental
stimuli and activity limitation. Scores range from 1 to 7,
with higher scores indicating fewer symptoms or better
HRQL. Intraclass correlation coefficients range from 0.89Health and Quality of Life Outcomes 2006, 4:51 http://www.hqlo.com/content/4/1/51
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to 0.94 between repeated assessments in stable patients
and there is evidence of clinical responsiveness and valid-
ity [15-17].
Developing preference weights
For this study, a combination of VAS and SG tasks were
used to generate the multi-attribute preference weighting
functions. The health state descriptions and visual props
were translated into UK English, Italian and French using
standardized translation and cultural adaptation proce-
dures. The VAS and SG scores provide the basic data for
deriving the multi-attribute utility functions [7]. The VAS
used the Feeling Thermometer as a visual prop [18]. This
was a vertical thermometer-shaped scale, 55 cm long, and
numerically scaled in units from 0 to 100. The top was
labeled "most desirable" and the bottom was labeled
"least desirable". For the VAS task, subjects were asked to
place the most preferred attribute level or state at 100, the
least preferred at 0, and the others in between. Ties were
allowed and the relative spacing between pairs of states
reflected the subject's judgment about the relative differ-
ences in desirability.
The first 5 VAS tasks were used to rate the 5 single-
attributes within the ASUI (i.e., cough, wheeze, shortness
of breath, sleep disturbance, side effects). For each
attribute the patient was given the full set of frequency-
severity levels marked on cards, with the best and worst
levels explicitly indicated. For each set of ratings, the sub-
ject was asked to assume that "all other aspects of your
health and abilities are normal". Patients were asked to
place the predefined best level at 100 and the predefined
worst level at 0 on the Feeling Thermometer. The remain-
ing levels were placed in any order by the patient. The fre-
quency-severity categories for each ASUI attribute were
rated separately.
The next VAS task involved rating 10 multi-attribute
states. The best and worst health states were placed at 100
and 0, respectively. The patient was given 5 corner states,
which include the worst frequency and severity category
for one attribute and no problems for the remaining four
attributes. The patient was asked to place the 5 corner
states on the Feeling Thermometer. Next, they were given
the 5 mixed multi-attribute states to place on the Feeling
Thermometer. These multi-attribute states varied the
severity and frequency of the 5 ASUI attributes (see Table
3). Finally, after preferences for all these states were rated,
the patient rated his/her current health.
The SG part of the interview utilized visual props to make
the task easier and more understandable for patients [18].
The SG interview required subjects to rate different hypo-
thetical health states based on a gamble between worst
asthma state (i.e., frequent and severe symptoms) and
best asthma state (i.e., no symptoms) or the certainty of
being in the hypothetical health state being measured. In
the SG, patients were asked to choose between living for
two weeks in the target health state and a gamble. The
gamble involved probabilities of either worst asthma state
or best asthma state starting with 100% chance of the best
state for two weeks and 0% chance of worst asthma state.
The probabilities of the best and worst states were then
varied until the respondent was indifferent or expressed a
dominant choice. To minimize respondent burden, each
subject was randomly assigned 1 of 3 sets of health state
cards to rate, each set containing 4 of the 10 multi-
attribute health states (i.e., corner and multi-symptom
states). Finally, all patients rated their current health on
the SG.
Data analysis
The data analyses consisted of five parts: (1) checking item
and scale distributions; (2) comparing VAS and SG utility
scores across countries; (3) developing the multi-attribute
utility functions for the ASUI based on the preference data
collected in each country; (4) comparing ASUI scores
based on country-specific MAUT functions; and (5) com-
paring the ASUI scores by clinician-rated asthma severity.
The country samples were compared on demographic
characteristics, and on mean ACQ score, AQLQ-S scores,
and clinician-rated severity measures.
ASUI-US scores were calculated based on the algorithm
from the US multi-attribute utility function [7] as follows:
ASUI = [1.20 (S1 × S2 × S3 × S4 × S5) - 1.20], where S1 =
cough; S2 = wheeze; S3 = dyspnea; S4 = awaken at night;
and S5 = side effects. The development of the ASUI prefer-
ence functions, based on the European data, followed the
procedures outlined by Torrance et al. [19] and used by
Revicki et al. [7] in developing the US-based ASUI. Prefer-
ence scores were inspected to identify illogical ratings. The
corner and multi-attribute health states were used in a
regression analysis, with no intercept, to develop the
power function for estimating utilities from VAS scores.
We then used these data to determine the multi-attribute
value and utility functions based on a multiplicative
model [7,20]. The VAS and SG scores for each country
were compared using a one-way ANOVA. The ASUI scores
were calculated based on the multi-attribute utility func-
tions derived from the data from each of the 3 countries.
These ASUI scores, based on the US, UK, French and Ital-
ian algorithms, were compared using a one-way ANOVA
and intraclass correlation coefficients (ICCs). The Spear-
man correlation coefficient was used to investigate the
relationship between the country-specific algorithm
derived ASUI scores and AQLQ-S domain scores and
severity scores. The relationship between clinician rated
asthma severity and mean ASUI scores, based on the com-Health and Quality of Life Outcomes 2006, 4:51 http://www.hqlo.com/content/4/1/51
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bined (total sample) multi-attribute utility function, were
compared using ANOVA.
Results
A total of 90 subjects completed the study, 30 in each
country (Italy, France, UK). All subjects provided consent
before participating in the study. Table 1 presents the soci-
odemographic characteristics of the sample by country. Of
the total sample, 56% were female, mean age was 45
years, the majority were living with others (64%), 66%
were employed full or part-time, and 46% had a univer-
sity or post-graduate degree. The percentage of patients
with mild (intermittent or persistent), moderate and
severe asthma, as defined by clinicians using GINA guide-
lines, was almost equal (36% mild, 31% moderate, 33%
severe). For clinician-rated severity scores, the only signif-
icant difference (p < 0.05) was between France and the
US. Sixty-three percent to 66% of subjects were rated as
having moderate to severe asthma.
There was very little missing data observed in this study.
There were no missing VAS or SG scores, and individual
ASUI item scores were missing in 0% to 6.6% of subjects.
Individual ACQ scores were incomplete in 0% to 6.6% of
subjects, and individual AQLQ-S item scores were missing
in 0% to 10% of subjects. However, most subjects had no
missing data on the ASUI, ACQ or AQLQ-S.
No significant differences were found between countries
on ACQ scores (p > 0.05; see Table 2). Mean AQLQ-S
overall and domain scores by country are presented in
Table 2. The mean overall AQLQ-S score was 4.73 for
Italy, 4.88 for the UK, 5.18 for France, and 5.22 for the US.
The distributional characteristics of VAS and SG scores by
country, including the US were compared. For the corner
states (states in which one attribute is described at the
worst level and the others are described at the best level),
mean VAS scores showed some variability across coun-
Table 1: Demographic and Clinical Characteristic of Study Sample
Characteristic Italy
N = 30
France
N = 30
UK
N = 30
US
N = 161
Gender (%)
Female 50 33 50 59
Male 50 67 50 41
Age in years
Mean (SD) 48 (12.5) 46 (16.3) 41 (15.1) 34.7 (10.7)
Marital status (%)1
Living alone 10 20 23
Living with someone 67 70 57
O t h e r 2 31 02 0
Employment status (%)
Full time paid employment 45 63 47 70
Part time paid employment 10 10 23 7
Unemployed 3 13 3 6
Retired 21 0 13 2
O t h e r 2 11 31 3 1 5
Educational attainment (%)
Elementary school 17 10 0 8
High school graduate 40 20 45 46
College graduate 27 20 52 25
Graduate degree 13 23 3 21
Other (e.g., technical school) 3 27 0
Co-morbidities (%)1
Arthritis 7 3 17
Low back pain 27 30 13
C a n c e r 330
Diabetes 7 7 3
Heart Disease 10 3 10
O t h e r 3 32 31 3
Physician-rated disease severity (%)
Mild Intermittent 20 7 13 26
Mild Persistent 13 30 23 32
Moderate 33 30 30 27
Severe 33 33 33 15
1Data not collected in the US studyHealth and Quality of Life Outcomes 2006, 4:51 http://www.hqlo.com/content/4/1/51
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tries, particularly for medication side effects (range from
0.17 in France to 0.44 in Italy). The ordinal ranking of cor-
ner states also varied, though severe dyspnea and severe
wheeze were consistently ranked least or second-least
desirable for all countries, with the exception of severe
wheeze in France. For four out of five multi-symptom
states, VAS scores were lowest in the US compared to the
other countries. Table 3 presents the ANOVA comparison
of VAS preferences for corner and multi-symptom health
states. Two corner states (severe awaken at night [p < .05]
and severe medication side effects [p < .001]) and all
multi-symptom states (p < .001) showed statistically sig-
nificant differences between countries in mean VAS
scores. The source for the difference in severe awaken at
night was for the mean comparison between France and
the US. Of the European countries, only France and the
UK had statistically significant difference in mean VAS
scores for any of the multi-symptom health states. VAS
Table 2: Descriptive Statistics for ACQ and AQLQ-S Scores by Country
Measure Italy
Mean (SD)
N = 30
France
Mean (SD)
N = 30
UK
Mean (SD)
N = 30
US
Mean (SD)
N = 161
Asthma Control Questionnaire
1.78 (1.01) 1.65 (1.06) 2.24 (1.14) 1.69 (1.64)*
Asthma Quality of Life Questionnaire – Standardized Version
Symptoms 4.64 (1.30) 5.17 (1.25) 4.57 (1.38) 5.12 (1.24)
Activity 4.91 (1.32) 5.38 (1.17) 5.36 (1.25) 5.43 (1.23)
Emotion 4.68 (1.51) 5.44 (1.36) 4.76 (1.41) 5.11 (1.57)
Environment 4.68 (1.57) 4.73 (1.59) 4.81 (1.33) 5.23 (1.36)
Overall Score 4.73 (1.19) 5.18 (1.19) 4.88 (1.23) 5.22 (1.20)
*Based on severity scale from 0 – 6, not the ACQ
Table 3: Comparison of VAS Preferences for Asthma Health States by Country
State Italy
Mean (SD)
N = 30
France
Mean (SD)
N = 30
UK
Mean (SD)
N = 30
US
Mean(SD)
N = 161
Overall
F Value
Paired Group
Comparisons
Corner Statesa
Severe cough 0.289 (0.245) 0.216 (0.167) 0.246 (0.224) 0.263 (0.254) 0.5
Severe wheeze 0.212 (0.211) 0.193 (0.130) 0.225 (0.185) 0.239 (0.255) 0.4
Severe dyspnea 0.125 (0.138) 0.149 (0.116) 0.227 (0.226) 0.158 (0.212) 1.5
Severe awaken at 
night
0.252 (0.190) 0.115 (0.143) 0.269 (0.267) 0.255 (0.246) 3.3* 5*
Severe medication 
side effects
0.439 (0.243) 0.171 (0.199) 0.345 (0.295) 0.253 (0.256) 7.0*** 1*** 3**
Multi-attribute Statesb
Moderate cough 
and dyspnea
0.584 (0.218) 0.488 (0.199) 0.660 (0.215) 0.309 (0.250) 27.1*** 3*** 4* 5** 6***
Moderate cough 
and wheeze
0.443 (0.230) 0.307 (0.159) 0.438 (0.223) 0.219 (0.201) 17.4*** 3*** 6***
Severe cough; 
moderate wheeze 
and dyspnea
0.296 (0.185) 0.181 (0.118) 0.355 (0.180) 0.172 (0.176) 12.5*** 3** 4** 6***
Severe cough; 
moderate wheeze, 
and awake at night
0.345 (0.200) 0.251 (0.196) 0.395 (0.195) 0.196 (0.201) 11.4*** 3** 6***
Severe cough, 
dyspnea, and 
awaken at night; 
moderate wheeze 
and side effects
0.112 (0.122) 0.072 (0.068) 0.193 (0.139) 0.075 (0.115) 9.4*** 4** 6***
Pairwise comparisons between means were performed using Scheffe's test of multiple comparisons.
1 = Italy vs. France, 2 = Italy vs. UK, 3 = Italy vs. US, 4 = France vs. UK, 5 = France vs. US, 6 = UK vs. US.
***<.001, ** <.01, *<.05.
a For corner states, one symptom is described as severe and frequent while other remaining symptoms reflect no problem.
b The multi-attribute states vary symptom severity as listed, with other remaining symptoms reflecting mild severity. Frequency remains constant 
for each symptom within each health state.Health and Quality of Life Outcomes 2006, 4:51 http://www.hqlo.com/content/4/1/51
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preferences were lowest in the US and highest in the UK
and Italy.
Similarly, SG scores were lowest in the US versus the Euro-
pean countries for all corner and multi-attribute health
states. The ordinal rankings of the multi-symptom states,
however, were consistent across all countries. The findings
from the ANOVA comparison of SG utilities for corner
and multi-symptom health states are summarized in
Table 4. Only three health states demonstrated statistically
significant differences between countries in mean SG util-
ity scores, severe wheeze (p < 0.001), moderate cough and
wheeze (p < 0.001), and moderate cough and dyspnea (p
< 0.001). In all cases, the source of these differences were
for the mean comparisons between the US and France (p
< 0.01 to p < 0.001) and the US and Italy (p < 0.01 to p <
0.001). In general, the US SG utilities were lower than
those of Italy, France, and the UK, and the utility scores
from France and Italy were comparable. Few substantive
differences were seen between the four country groups,
given that for 7 of 10 (70%) health states there were no
statistically significant differences in mean SG utility
scores among countries.
We attempted to fit similar multi-attribute utility function
models as those determined from the earlier US study
data to the data from Italy, France, and the UK. For the
UK, a multiplicative multi-attribute utility function was
acceptable and was fit to these data. For France and Italy,
there was no support for the multiplicative function, and
additive function models were fit. Given these observed
differences in deriving ASUI weighing algorithms, we also
determined the best model (i.e., additive or multiplica-
tive) for the combined US, UK, French, and Italian data.
For the combined data, we were able to fit a multiplicative
multi-attribute utility function and derived ASUI scores
based on this algorithm. Therefore, in this study we
derived 5 different ASUI scores based on the US (ASUI-
US), UK (ASUI-UK), French (ASUI-FR), Italian (ASUI-IT),
and combined sample algorithms (ASUI-ALL).
Mean ASUI scores for each sample were calculated using
each country-specific scoring algorithm and are provided
in Table 5. Mean ASUI scores were lowest for all samples
when calculated using the US scoring algorithm, with
mean scores ranging from 0.63 for the UK sample to 0.77
for both the French and Italian samples. Mean scores
Table 4: Comparison of SG Utilities for Asthma Health States by Country
State Italy
Mean(SD)
N = 30
France
Mean(SD)
N = 30
UK
Mean(SD)
N = 30
US
Mean(SD)
N = 161
Overall
F Value
Paired Group
Comparisons
Corner States a
Severe cough 0.795 (0.121) 0.850 (0.176) 0.755 (0.148) 0.689 (0.213) 2.5
Severe wheeze 0.870 (0.103) 0.880 (0.067) 0.765 (0.172) 0.661 (0.208) 7.3*** 3* 5*
Severe dyspnea 0.720 (0.236) 0.760 (0.191) 0.710 (0.165) 0.602 (0.246) 2.0
Severe awaken at 
night
0.860 (0.145) 0.750 (0.176) 0.780 (0.157) 0.667 (0.247) 2.6
Severe medication 
side effects
0.850 (0.189) 0.775 (0.118) 0.795 (0.174) 0.662 (0.230) 3.3*
Multi-symptom Statesb
Moderate cough 
and dyspnea
0.835 (0.173) 0.835 (0.099) 0.715 (0.198) 0.674 (0.234) 5.1** 3* 5*
Moderate cough 
and wheeze
0.778 (0.180) 0.780 (0.130) 0.675 (0.168) 0.600 (0.241) 5.9*** 3* 5*
Severe cough 
moderate wheeze 
and dyspnea
0.730 (0.193) 0.800 (0.118) 0.755 (0.146) 0.615 (0.212) 3.8*
Severe cough; 
moderate wheeze, 
dyspnea, and 
awake at night
0.720 (0.250) 0.760 (0.120) 0.675 (0.177) 0.589 (0.243) 2.6
Severe cough, 
dyspnea, and 
awaken at night; 
moderate wheeze 
and side effects
0.640 (0.313) 0.630 (0.210) 0.665 (0.189) 0.455 (0.275) 3.3*
Pairwise comparisons between means were performed using Scheffe's test of multiple comparisons.
1 = Italy vs. France, 2 = Italy vs. UK, 3 = Italy vs. US, 4 = France vs. UK, 5 = France vs. US, 6 = UK vs. US.
***<.001,**<.01,*<.05.
a For corner states, one symptom is described as severe and frequent while other remaining symptoms reflect no problem.
b The multi-attribute states vary symptom severity as listed, with other remaining symptoms reflecting mild severity. Frequency remains constant 
for each symptom within each health state.Health and Quality of Life Outcomes 2006, 4:51 http://www.hqlo.com/content/4/1/51
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ranged from 0.86 (UK) to 0.93 (US) using the Italian algo-
rithm, 0.88 (UK) to 0.95 (US) using the French algorithm,
and 0.86 (UK) to 0.93 (US, Italy) using the UK algorithm.
Using the combined sample algorithm, the mean score for
the UK sample was 0.76 and for the US, French, and Ital-
ian samples was 0.86.
Table 6 presents mean ASUI scores for the total sample
(US, UK, Italy, and France) as calculated using each coun-
try-specific algorithm and the combined sample algo-
rithm. The mean was lowest using the US algorithm
(0.75) and highest using the French algorithm (0.94).
Pairwise comparisons between means were performed
using Scheffe's test of multiple comparisons. Statistically
significant (p < .001) differences in mean ASUI scores
were found for 7 of 10 paired comparisons of country-spe-
cific algorithms. Mean scores using the Italian, French,
and UK algorithms (Italy vs. France, Italy vs. UK, France
vs. UK) were not significantly different. The ASUI scores
based on the country-specific algorithms were correlated
from 0.971 to 0.995 (p < 0.0001). The ICCs comparing
the country-specific ASUI scores ranged from 0.44 (ASUI-
US and ASUI-FR) to 0.97 (ASUI-FR versus ASUI-IT), with
70% of ICCs greater than 0.74.
Using the combined algorithm for the total sample, mean
ASUI scores decreased with increased asthma severity, as
rated by the clinician (mild intermittent – 0.94, mild per-
sistent – 0.90, moderate – 0.83, severe – 0.72) (p <
0.0001; see Figure 1).
Spearman correlations between each country-specific
algorithm based ASUI scores and the AQLQ-S domain
and overall, ACQ and clinician-rated severity scores were
calculated (Table 7). Correlations between ASUI scores
and AQLQ-S domain and ACQ scores were generally
moderate to high and statistically significant (p < 0.0001)
regardless of algorithm. Correlations between ASUI scores
and clinician-rated severity scores were generally not as
high as those between ASUI and AQLQ-S and ACQ scores.
Most importantly, the magnitude and direction of correla-
tions between the ACQ and clinician-rated severity meas-
ures and the various ASUI scores were comparable. The
relationship between the AQLQ-S scores and the ASUI
scores generated by the country-specific algorithms were
also comparable.
Discussion
This study evaluated whether the preferences and utilities
for asthma symptom-related health states were compara-
ble across a sample of asthma patients from the US and
selected European countries. In addition, we evaluated the
multi-attribute utility functions derived from these coun-
try-specific preference/utility data. We found evidence
that asthma patients in different countries rate the same
symptom-defined health states somewhat differently.
Although there were few differences in the SG utilities for
Table 5: Descriptive Statistics and Distributional Characteristics 
of ASUI Scores using Country-Specific Algorithms
Sample Mean (SD) Median Range
(Min/Max)
US Algorithm
US 0.76 (0.19) 0.78 0.08–1.00
France 0.77 (0.22) 0.84 0.30–1.00
Italy 0.77 (0.20) 0.82 0.13–1.00
UK 0.63 (0.23) 0.63 0.19–1.00
Italian Algorithm
US 0.93 (0.12) 0.97 0.18–1.00
France 0.92 (0.13) 0.97 0.54–1.00
Italy 0.92 (0.17) 0.99 0.17–1.00
UK 0.86 (0.16) 0.91 0.38–1.00
French Algorithm
US 0.95 (0.11) 0.99 0.13–1.00
France 0.94 (0.11) 0.99 0.66–1.00
Italy 0.94 (0.15) 1.00 0.23–1.00
UK 0.88 (0.15) 0.94 0.42–1.00
UK Algorithm
US 0.93 (0.09) 0.96 0.45–1.00
France 0.92 (0.10) 0.98 0.66–1.00
Italy 0.93 (0.11) 0.97 0.48–1.00
UK 0.86 (0.12) 0.89 0.55–1.00
Combined Algorithm
US 0.86 (0.14) 0.90 0.16–1.00
France 0.86 (0.17) 0.93 0.45–1.00
Italy 0.86 (0.17) 0.91 0.21–1.00
UK 0.76 (0.19) 0.79 0.30–1.00
Table 6: Descriptive Statistics and Distributional Characteristics of ASUI Scores by Country Algorithm in Total Sample**
Algorithm Mean (SD) Median Range
(Min/Max)
Floor (%)* Ceiling (%)*
US 0.75 (0.20) 0.78 (0.08–1.00) 0.41 12.60
France 0.94 (0.12) 0.99 (0.13–1.00) 0.41 14.63
Italy 0.92 (0.13) 0.97 (0.17–1.00) 0.41 12.60
UK 0.92 (0.10) 0.96 (0.45–1.00) 0.41 12.60
All 0.85 (0.16) 0.90 (0.16–1.00) 0.41 12.60
* Floor = percent who answered minimum value; Ceiling = percent who answered maximum value
** All pairwise comparisons between means were statistically significant at p < .0001 except Italy vs. UK (p = 0.9234).Health and Quality of Life Outcomes 2006, 4:51 http://www.hqlo.com/content/4/1/51
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the corner and multiple symptom states, we did observe
differences on the severe wheeze corner state and the
moderate level multi-symptom states (involving cough
and wheeze and cough and dyspnea). In all cases, the dif-
ferences were mainly between the US and Italian sample
and between the US and French sample utility estimates.
The US subjects tended to rate these health states as worse
than the Italian and French subjects. It is likely that cul-
tural differences in perception and valuation of some
asthma symptoms may exist, and that these differences
were expressed between the French and Italian subjects
and those from the US. It is interesting to note that the UK
subjects reported utilities that were between those
reported by the US and the French and Italian samples.
As expected, there were differences between mean VAS
preference and SG utility scores for the multi-attribute
asthma states. Differences of this magnitude have been
observed in previous studies [8,21-23]. The differences
observed are likely due to the differences in the VAS and
SG methods for collecting preferences; for example, the
SG method introduces risk into the assessment of utilities.
In addition, the SG utilities were derived using a 2 week
time period which was done to capture the variations in
symptom experience for patients with asthma. This was
the identical approach taken in the U.S. study [7]. Longer
time periods for the SG exercise might have resulted in dif-
ferent preference scores.
The generated multi-attribute utility functions for the
ASUI differed between the different countries. Based on
the US and the UK data, a multiplicative multi-attribute
utility function was fit to the utility data, while the French
and Italian data supported an additive model. The result-
ant ASUI scores were significantly higher for the UK,
French, and Italian based algorithms compared with the
US algorithm. The combined data algorithm was based on
a multiplicative multi-attribute utility function, and the
resultant mean ASUI scores differed significantly from the
US based, UK based, Italian based, and French based ASUI
scores. Clearly, there are differences in mean ASUI scores
among the different preference weighting algorithms.
Based on these data, the US derived algorithm may not fit
the preference structure of asthma patients from France or
Italy.
We examined the correlations among the different coun-
try-specific algorithm derived ASUI scores and found sig-
nificant correlations among the different scores. The
strength of these correlations suggest that although the
distribution of the different ASUI scores may be shifted
toward lower or higher scores, the relative rank ordering
of mean scores in patients with asthma symptoms are
maintained. This is further supported by the relationships
observed between the 5 different ASUI scores and the
AQLQ-S scores, the ACQ and clinician-rated disease sever-
ity. The observed results for the total sample indicate very
comparable correlations between the different ASUI
Table 7: Spearman Correlations Between ASUI and AQLQ-S Domain and Overall Scores, Adequacy of Asthma Control (ACQ), and 
Clinician-Rated Severity of Disease
ASUI
Country-specific Algorithm
ASUI-US ASUI-UK ASUI-FR ASUI-IT ASUI-ALL
Asthma Quality of Life Questionnaire
Symptom 0.829 0.827 0.812 0.814 0.829
Activity limitation 0.624 0.632 0.639 0.637 0.635
Emotional function 0.609 0.596 0.589 0.589 0.606
Environmental stimuli 0.551 0.570 0.564 0.565 0.564
Overall Score 0.733 0.735 0.729 0.729 0.738
Asthma Control Questionnaire -0.610 -0.616 -0.594 -0.589 -0.611
Clinician-rated Severity -0.496 -0.494 -0.485 -0.478 -0.501
*All combinations are significant at p < .0001
Mean ASUI Scores (Combined Algorithm) by Clinician-Rated  Disease Severity: Total Sample (UK, Italy, France, US) Figure 1
Mean ASUI Scores (Combined Algorithm) by Clinician-Rated 
Disease Severity: Total Sample (UK, Italy, France, US).
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scores and the asthma-specific quality of life scores. For
example, AQLQ-S symptom scores were correlated from
0.81 (for ASUI-FR or ASUI-IT) to 0.83 (for ASUI-US or
ASUI-ALL) with the different ASUI scores, and larger cor-
relations were seen between ASUI scores and AQLQ-S
symptom scores than for environmental stimuli, activity
limitation, and emotional function scores. More impor-
tantly, comparable magnitude correlations were seen
between the ASUI scores and clinician ratings of asthma
severity. When the mean ASUI score from the combined
sample algorithm is compared by physician-rated asthma
severity groups, we observe that patients with severe per-
sistent asthma have ASUI scores that are significantly
lower than those with less severe asthma severity. These
findings are consistent with those reported in the original
ASUI development study [7].
The findings of this study should be interpreted in light of
several study limitations. First, the measures of disease
severity differed somewhat between the European and US
samples. The clinician-rated severity for the European
study was based on GINA guidelines, while asthma sever-
ity for the US study was based on physician global assess-
ment of severity from mild to severe. Second, the VAS
preference and SG utility interviews were completed for
all health states in the US sample, but in only a sub-sam-
ple of subjects in Europe. There were fewer available data
on which to base mean SG utilities in Europe and this may
have resulted in somewhat unstable utilities for the health
states. Finally, the sample sizes by country for Europe were
30 each, compared with 161 in the US sample. Given the
relatively small samples, one or two respondent prefer-
ence ratings, based on different clinical characteristics,
could potentially skew the findings. Additional research is
needed to confirm these utility and preference estimates
in the European samples.
Conclusion
In summary, the results of this study indicate that prefer-
ences for asthma-related symptoms and multiple symp-
tom states differ between France and Italy and the UK and
the US. Because of these differences, the multi-attribute
utility functions derived within countries were somewhat
different. Despite these differences, the results indicate
that each of the derived algorithms captures a similar rank
ordering of patients by disease severity, although the ASUI
score distributions may be shifted somewhat. Therefore,
as long as the same algorithm is used within an interna-
tional clinical trial, the relative ordering of mean ASUI
scores by disease severity is preserved. The greater range of
ASUI scores, based on the US or combined algorithm, sug-
gests that either of these two algorithms may be more
responsive to changes in clinical status within clinical tri-
als. However, data on the responsiveness of the ASUI
scores requires further research. The ASUI represents a use-
ful and valid measure of preference-weighted asthma
symptoms for use in clinical trials and clinical manage-
ment. The findings of this study suggest that the ASUI may
be a complementary patient-reported outcome for clinical
studies and may be useful for applications in cost-effec-
tiveness studies comparing different asthma treatments.
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